Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of $0.02, $0.02 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $36.7 million versus the consensus estimate of $33.44 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.